Flush with cash, computational chemistry pioneer Nimbus considers next steps. Is an IPO in the future?
When Bruce Booth helped launch Nimbus Therapeutics back in 2009, it was difficult to find co-investors willing to back the company’s pioneering computational chemistry platform. Those were the “leaner times for the sector,” he said, and the budget was tight.
That all ended when Gilead inked a massive $1.2 billion NASH deal with Nimbus in 2016. And the cash keeps flowing for the Cambridge, MA-based biotech.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.